Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

SXTPW

60 Degrees Pharmaceuticals (SXTPW)

60 Degrees Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SXTPW
DateTimeSourceHeadlineSymbolCompany
31/05/202404:15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
30/05/202421:59GlobeNewswire Inc.Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its KindNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
22/05/202410:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
22/05/202410:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
22/05/202410:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
22/05/202410:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
22/05/202410:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
20/05/202421:59GlobeNewswire Inc.60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine StudyNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
16/05/202403:45GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces First Quarter 2024 ResultsNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
16/05/202401:56Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
08/05/202421:59GlobeNewswire Inc.60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious DiseasesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
02/05/202421:59GlobeNewswire Inc.60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes RequiredNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
03/04/202422:58GlobeNewswire Inc.60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine BabesiosisNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
14/03/202422:59GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024NASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
20/02/202423:59GlobeNewswire Inc.60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida aurisNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
08/02/202423:59GlobeNewswire Inc.60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial OfficerNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
01/02/202403:15GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public OfferingNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
31/01/202401:00GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public OfferingNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
22/01/202423:59GlobeNewswire Inc.60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA MeetingNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
16/01/202423:59GlobeNewswire Inc.60 Degrees Pharma Regains Compliance with Nasdaq Listing RequirementsNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
26/12/202323:59GlobeNewswire Inc.60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024NASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
15/11/202323:29GlobeNewswire Inc.60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne DiseaseNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
19/10/202323:31GlobeNewswire Inc.60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in BostonNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
13/10/202307:16GlobeNewswire Inc.60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne DiseasesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
19/09/202306:16GlobeNewswire Inc.60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA RequirementsNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
06/09/202321:31GlobeNewswire Inc.60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
30/08/202321:32GlobeNewswire Inc.60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal ActivityNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
22/08/202321:31GlobeNewswire Inc.60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum MalariaNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
15/08/202321:31GlobeNewswire Inc.60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.govNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
31/07/202321:59GlobeNewswire Inc.60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive SubjectsNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SXTPW